Back to results
US 2023/0399312 A1Published application
Substituted pyrimidines and methods of use
AssigneeTheravance Biopharma R&D IP, LLC
InventorsMandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
Life of this patent
Estimating the term…
Abstract
The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
Claims38
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- A is selected from phenyl, 5- to 6-membered heteroaryl, indanyl, indazolyl, benzotriazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxanyl, and tetrahydrobenzazepinyl;
- B is selected from phenyl and 5- to 6-membered heteroaryl;
- RA is independently selected at each occurrence from:
- halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3;
- C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, —C(O)OR1, C3-8 carbocycle, and 3- to 10-membered heterocycle;
- and
- C3-8 carbocycle and 3- to 10-membered heterocycle,
- wherein each C3-8 carbocycle and 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —CH2N(R1)2, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, R1, and C1-6 alkyl;
- RB is independently selected at each occurrence from halogen, —CN, —NH2, —NHCH3, —NHCH2CH3, —C(O)CH3, —OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2F, —CHF2, —CF3, C3-4 carbocycle, and 3- to 4-membered heterocycle;
- m is 0, 1 or 2;
- n is 0, 1, 2, or 3;
- R1 is independently selected at each occurrence from hydrogen;
- and C1-6 alkyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-8 carbocycle), and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —NH2, —NHCH3, —N(CH3)2, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-8 carbocycle, and 3- to 6-membered heterocycle;
- and
- R2 and R3 are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R1.
13 more elements
-3. (canceled)
-10. (canceled)
-13. (canceled)
-21. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-40. (canceled)
-43. (canceled)
(canceled)
-50. (canceled)
(canceled)
-63. (canceled)
Dependencies are inferred from the claim text.